Cat. No. | Product name | CAS No. |
DCC1808 |
Displurigen
Inhibitor of ATPase activity of HSP70 |
96156-26-2 |
DCC1809 |
Distamycin A Hydrochloride
Antibiotic, specifically inhibiting the initiation of RNA synthesis, binding isohelically to the minor groove of B-DNA at A/T rich sites |
6576-51-8 |
DCC1810 |
Distigmine Dibromide
Parasympathomimetic with longer duration of action |
15876-67-2 |
DCC1811 |
Djt06001
Novel selective Factor Xa inhibitor, reducing thrombus formation with low risk of bleeding |
1628182-40-0 |
DCC1812 |
Dk-1-150
Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line |
|
DCC1813 |
Dk-1-166
Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line |
2204279-20-7 |
DCC1814 |
Dk-139
Inhibitor of NF-kappaB-mediated GROalpha expression, suppressing the TNFalpha-induced invasive capability of MDA-MB-231 human breast cancer cells |
1426059-23-5 |
DCC1815 |
Dk-1-49
Novel autophagonizer, inducing autophagic cell death in apoptosis-defective cell line |
853136-76-2 |
DCC1816 |
Dl0410
Novel acetylcholinesterase inhibitor, promoting synaptic function and neuronal survival, ameliorating cognitive deficits in SAMP8 mice via improved mitochondrial dynamics and increased activity of the NMDAR-CREB-BDNF pathway |
|
DCC1817 |
D-lana-14
Novel potent anti-MRSA agent, disrupting biofilms with no resistance development, sensitizing rifampicin and tetracycline against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa |
|
DCC1818 |
Dlc27-14
Specific protein disorder catalyzer of HIV-1 Nef |
1360869-92-6 |
DCC1819 |
Dl-threo-dihydrosphingosine
Competitive inhibitor of both SPHK1 and SPHK2 |
2304-75-8 |
DCC1820 |
D-luciferin Phosphate Sodium Salt
Ultrasensitive bioluminogenic enzyme substrate |
145613-12-3 |
DCC1821 |
D-lys(z)-pro-arg-pna
Chromogenic peptide substrate, being highly sensitive for the measurement of activated Protein C. |
108963-69-5 |
DCC1822 |
Dma-cpptl
Prodrug of CPPTL, inducing apoptosis in a dose-dependent manner via the ROS/JNK pathway in acute myeloid leukemia |
|
DCC1823 |
Dmako-20
Novel multi-target anticancer prodrug activated by the tumor specific CYP1B1 enzyme, potently inhibiting HCT-15, HCT-116 and K562 cells growth, showing moderate anti-proliferative activity towards MDA-MB-231, HepG2, PANC, Bel7402 and MGC803 cancer cells, |
|
DCC1824 |
Dmako-5
Novel antineoplastic agent, exhibiting remarkable anticancer activity as well as excellent cellular selectivity |
|
DCC1825 |
D-mannuronic Acid [6906-37-2]
Novel blocker of the TLR2 and TLR4 downstream signaling pathway, effectively inhibiting mRNA expression of MyD88 and p65, major subunit of nuclear factor-kappaB |
6906-37-2 |
DCC1826 |
Dmb213
Novel non-nucleoside inhibitor of Zika viral RNA-dependent RNA polymerase (RdRp) enzymes |
|
DCC1827 |
Dmcl1-2
Novel potent and selective PROTAC degrader of myeloid cell leukemia 1 (MCL1) |
2351218-88-5 |
DCC1828 |
Dmnpe-caged Luciferin
Novel cell permeable caged Luciferin |
223920-67-0 |
DCC1829 |
Dmocptl
Novel inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells |